Nature

Demodex Mite Infestation and Associated Conditions

The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...
The American Journal of Managed Care

Lotilaner Is Effective, Accessible Method of Treating Demodex Blepharitis

I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis. During the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from February ...
FOX8 Cleveland

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available ...
KTLA

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...
USA Today

Eyelash mites (yikes!) are a lot more common than most people realize

The idea of tiny bugs living in your eyelashes might sound like something out of a horror movie, but their reality is far less alarming. Microscopic mites are incredibly common and, for the most part, ...
NBC DFW

Itchy eyes? Maybe it's mites. Maybe it's allergies. Definitely be cautious

Waking up with itchy eyelids might seem like a typical allergy symptom, but it could also be a sign of eye mites. Eye mites, or Demodex, are microscopic organisms that live at the base of your ...
WDAF-TV

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...